Manuel Constenla

3.9k total citations · 1 hit paper
53 papers, 3.1k citations indexed

About

Manuel Constenla is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Manuel Constenla has authored 53 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Oncology, 27 papers in Pulmonary and Respiratory Medicine and 10 papers in Cancer Research. Recurrent topics in Manuel Constenla's work include Colorectal Cancer Treatments and Studies (15 papers), Lung Cancer Treatments and Mutations (14 papers) and Neutropenia and Cancer Infections (12 papers). Manuel Constenla is often cited by papers focused on Colorectal Cancer Treatments and Studies (15 papers), Lung Cancer Treatments and Mutations (14 papers) and Neutropenia and Cancer Infections (12 papers). Manuel Constenla collaborates with scholars based in Spain, Germany and United Kingdom. Manuel Constenla's co-authors include Alejandro Majlis, Vladimir Moiseyenko, C. Boni, Jaffer A. Ajani, Eric Van Cutsem, Yee Chao, Adriano Rodrigues, M Fodor, Э К Возный and Sergei Tjulandin and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Manuel Constenla

53 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group

2006 1.5k citations Manuel Constenla et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Manuel Constenla Spain	19	2.2k	2.0k	909	591	312	53	3.1k
Jonathan Wadsley United Kingdom	20	1.3k 0.6×	1.2k 0.6×	992 1.1×	320 0.5×	229 0.7×	89	2.3k
Daisuke Takahari Japan	29	1.7k 0.8×	1.8k 0.9×	845 0.9×	524 0.9×	498 1.6×	217	3.1k
Hirofumi Yasui Japan	24	1.5k 0.7×	1.2k 0.6×	1.1k 1.2×	426 0.7×	250 0.8×	159	2.4k
Atsuo Takashima Japan	30	1.5k 0.7×	1.7k 0.8×	923 1.0×	438 0.7×	388 1.2×	222	2.9k
Daniel Vallböhmer Germany	36	1.9k 0.9×	1.4k 0.7×	2.0k 2.2×	321 0.5×	833 2.7×	138	3.7k
B Paillot France	28	2.8k 1.3×	1.9k 1.0×	2.4k 2.6×	201 0.3×	388 1.2×	63	4.3k
Э К Возный Portugal	5	1.6k 0.7×	1.3k 0.6×	784 0.9×	568 1.0×	204 0.7×	6	2.5k
Masahiko Tsurumaru Japan	25	1.9k 0.9×	587 0.3×	2.2k 2.4×	215 0.4×	296 0.9×	131	3.0k
Heung Moon Chang South Korea	27	1.2k 0.6×	1.3k 0.7×	816 0.9×	581 1.0×	226 0.7×	80	2.2k
Dae Young Zang South Korea	27	1.3k 0.6×	1.1k 0.6×	593 0.7×	434 0.7×	558 1.8×	184	2.6k

Countries citing papers authored by Manuel Constenla

Since Specialization

Citations

This map shows the geographic impact of Manuel Constenla's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Manuel Constenla with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Manuel Constenla more than expected).

Fields of papers citing papers by Manuel Constenla

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Manuel Constenla. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Manuel Constenla. The network helps show where Manuel Constenla may publish in the future.

Co-authorship network of co-authors of Manuel Constenla

This figure shows the co-authorship network connecting the top 25 collaborators of Manuel Constenla. A scholar is included among the top collaborators of Manuel Constenla based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Manuel Constenla. Manuel Constenla is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Camps, Carlos, Antonio Antón, Juan Jesús Cruz, et al.. (2019). <p>Working towards a consensus on the oncological approach of breakthrough pain: a Delphi survey of Spanish experts</p>. Journal of Pain Research. Volume 12. 2349–2358. 8 indexed citations

Arriola, Edurne, Ronald G. García, Manuel Constenla, et al.. (2018). Comparison of plasma ctDNA and tissue/cytology-based techniques for the detection of EGFR mutation status in advanced NSCLC: Spanish data subset from ASSESS. Clinical & Translational Oncology. 20(10). 1261–1267. 20 indexed citations

Cueva, Juan, Silvia Antolín, Lourdes Calvo, et al.. (2017). Galician consensus on management of cardiotoxicity in breast cancer: risk factors, prevention, and early intervention. Clinical & Translational Oncology. 19(9). 1067–1078. 10 indexed citations

Arriola, Edurne, Alfredo Paredes, Ramón García Gómez, et al.. (2016). 147P: Level of concordance between EGFR mutation status obtained from tissue/cytology and blood (plasma) for advanced non-small-cell lung cancer in Spain: ASSESS study. Journal of Thoracic Oncology. 11(4). S122–S122. 1 indexed citations

Borró, J.M., et al.. (2016). Estudio comparativo de la supervivencia tras procedimientos videotoracoscópicos para la lobectomía del cáncer de pulmón: abordaje por puerto único frente a múltiple. Archivos de Bronconeumología. 53(4). 199–205. 5 indexed citations

Garrido, Pilar, et al.. (2014). Darbepoetin alfa administered once every three weeks for the treatment of anemia in elderly patients with non-myeloid tumors receiving chemotherapy.. PubMed. 100(2). 225–31. 1 indexed citations

Alonso, Vicente, Carles Pericay, P. Escudero, et al.. (2010). Cetuximab Given Every 2 Weeks plus Irinotecan Is an Active and Safe Option for Previously Treated Patients with Metastatic Colorectal Cancer. Chemotherapy. 56(2). 142–146. 18 indexed citations

Schwenkglenks, Matthias, Ruth Pettengell, Christian Jackisch, et al.. (2010). Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU Prospective Observational European Neutropenia Study. Supportive Care in Cancer. 19(4). 483–490. 45 indexed citations

Pettengell, Ruth, André Bosly, Thomas D. Szucs, et al.. (2008). Multivariate analysis of febrile neutropenia occurrence in patients with non‐Hodgkin lymphoma: data from the INC‐EU Prospective Observational European Neutropenia Study. British Journal of Haematology. 144(5). 677–685. 79 indexed citations

10.

Romieu, Gilles, Michael Clemens, Rolf Mahlberg, et al.. (2007). Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: A randomized phase 2 trial. Critical Reviews in Oncology/Hematology. 64(1). 64–72. 33 indexed citations

11.

Schwenkglenks, Matthias, Christian Jackisch, Manuel Constenla, et al.. (2006). Neutropenic event risk and impaired chemotherapy delivery in six European audits of breast cancer treatment. Supportive Care in Cancer. 14(9). 901–909. 46 indexed citations

12.

León, Xavier, Ricardo Hitt, Manuel Constenla, et al.. (2005). A Retrospective Analysis of the Outcome of Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Refractory to a Platinum-based Chemotherapy. Clinical Oncology. 17(6). 418–424. 139 indexed citations

13.

Font, Albert, A Murias, Cristina Martín, et al.. (2005). Sequential mitoxantrone/prednisone followed by docetaxel/estramustine in patients with hormone refractory metastatic prostate cancer: results of a phase II study. Annals of Oncology. 16(3). 419–424. 13 indexed citations

14.

Pérez-Manga, G., Manuel Constenla, A. Ruíz, et al.. (2004). Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer. British Journal of Cancer. 90(9). 1740–1746. 42 indexed citations

15.

Leonard, Robert, Jeffrey Crawford, André Bosly, et al.. (2003). Delivering optimal adjuvant chemotherapy in primary breast cancer: the role of rHuG-CSF. European Journal of Cancer Supplements. 1(9). 1–12. 5 indexed citations

16.

Viéitez, José María, M. González‐Barón, J. R. Mel, et al.. (2002). Phase II study of carboplatin and 1-h intravenous etoposide and paclitaxel in a novel sequence as first-line treatment of patients with small-cell lung cancer. Lung Cancer. 39(1). 77–84. 3 indexed citations

17.

Constenla, Manuel, et al.. (2002). Response predicting factors to recombinant human erythropoietin in cancer patients undergoing platinum‐based chemotherapy. Cancer. 95(11). 2408–2413. 11 indexed citations

18.

López, Antonio Irigoyen, et al.. (2001). Phase II study of irinotecan as first-line chemotherapy for patients with advanced colorectal carcinoma. Cancer. 91(4). 704–711. 12 indexed citations

19.

Feliú, Jaime, et al.. (2000). Phase II trial of gemcitabine and UFT modulated by leucovorin in patients with advanced pancreatic carcinoma. Cancer. 89(8). 1706–1713. 30 indexed citations

20.

Frau, Alessandra, Agustí Barnadas, Miguel Méndez, et al.. (1999). Phase II study of ifosfamide plus vinorelbine in metastatic breast cancer patients previously treated with combination chemotherapy. Cancer Chemotherapy and Pharmacology. 44(7). S5–S8. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact